Press Releases (-) Any 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2012 March 18, 2012 arGEN-X launches NHance™ technology to generate better human antibody therapies February 27, 2012 arGEN-X enters into a therapeutic antibody alliance with Shire February 7, 2012 arGEN-X advances a third therapeutic antibody program into preclinical development 2011 November 30, 2011 arGEN-X raises EUR 27.5 million (USD 37 million) in oversubscribed Series B round November 29, 2011 arGEN-X is awarded €1.3 million IWT Grant to Advance Proprietary SIMPLE Antibody™ Platform for Addressing Challenging Disease Targets September 6, 2011 arGEN-X presents significant progress at Biopharm America 2011 July 25, 2011 arGEN-X announces non-exclusive license with BioWa for Potelligent® technology May 15, 2011 arGEN-X initiates a second pre-clinical development program in under 18 months from start of operations January 4, 2011 arGEN-X signs discovery and development alliance with Lilly 2010 November 4, 2010 arGEN-X appoints Dr Debbie Allen as Senior Director Business Development September 26, 2010 arGEN-X awarded €1.5 million iwt grant to accelerate pre-clinical antibody development July 7, 2010 arGEN-X granted broad patent covering its unique simple antibody™ platform Pagination First page « First Previous page ‹ Previous … Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Current page 27 Page 28 Next page Next › Last page Last »
